Sign up

For Our 100% Free Stock Alerts!

Adept Technology Receives $820K Order for Vision-Guided Robots

Adept Technology Receives $820K Order for Vision-Guided Robots

Leading Global Consumer Electronics Manufacturer Selects Adept for Capacity Expansion PLEASANTON, Calif., Feb. 22, 2012 (CRWENEWSWIRE) -- Adept Technology, Inc. (Nasdaq:ADEP), a leading provider of intelligent robots and autonomous mobile solutions, today announced it has received a $820 thousand dollar order for...Read more

The Hackett Group Announces Fourth Quarter Results and $55 Million Stock Repurchase Tender Offer

The Hackett Group Announces Fourth Quarter Results and $55 Million Stock Repurchase Tender Offer

  * Q4 2011 revenue of $55.5 million and pro forma EPS of $0.09, both at high-end of guidance * Fiscal year revenue of $225.1 million, up 12%, with pro-forma EBITDA of $24.7 million, up 20% MIAMI -- (CRWENEWSWIRE) -- The Hackett Group, Inc. (NASDAQ:HCKT), a global strategic advisory and operations improvemen...Read more

Sourcefire Announces Record Revenue for Fourth Quarter & Full Year 2011

Sourcefire Announces Record Revenue for Fourth Quarter & Full Year 2011

Fourth Quarter 2011: * Revenue: $53.2 million, an increase of 40% year-over-year * Adjusted Net Income: $7.6 million, or $0.25 per diluted share Full Year 2011: * Revenue: $165.6 million, an increase of 27% year-over-year * Adjusted Net Income: $16.8 million, or $0.57 per diluted share COLUMBIA, MD -- 02/21/2012 ...Read more

ITT Announces Global Supply Agreeement with Shell Global Solutions

ITT Announces Global Supply Agreeement with Shell Global Solutions

  SENECA FALLS, NY -- 02/21/2012 (CRWENEWSWIRE) -- ITT Corporation (NYSE:ITT) announced today an Enterprise Framework Agreement with Shell Global Solutions in which ITT’s Goulds Pumps brand will provide American Petroleum Institute (API) centrifugal pumps to support Shell operations worldwide. Shell Glob...Read more

Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer

Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer

  Primary endpoint of Progression Free Survival was met with hazard ratio of 0.61 (p = 0.005). The combination therapy was well tolerated with a safety profile consistent with prior studies. SOUTH SAN FRANCISCO, CA -- (CRWENEWSWIRE) -02/21/12- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announc...Read more

  • Exclusive Videos











  • Hot stocks to watch!

    Symantec Corp - SYMC

    Hewlett-Packard Co - HPQ

    Marshall & Ilsley Corp - MI

    General Electric Co - GE

    SPDR S&P 500 ETF - SPY

    Financial Select Sector SPDR ETF - XLF

    Mylan Laboratories Inc - MYL

    ProShares UltraShort 20+ Year - TBT

    Cleantech Transit, Inc. - CLNO.OB

    iShares Down Jones U.S. Real Estate Index - IYR

    ProShares Ultra S&P500 ETF - SSO

    Mela Sciences Inc - MELA

    Gilead Sciences Inc - GILD

    MGM Mirage Inc - MGM

    iShares MSCI EAFE Index ETF - EFA

    Seagate Technology Plc - STX

    ProShares UltraShort S&P500 ETF - SDS

    Isilon Systems Inc - ISLN

    Crown Equity Holdings Inc. - CRWE.OB

    Corning Inc - GLW

    eBay Inc - EBAY

    Advanced Micro Devices - AMD

  • Crown Tele Services

     
     
     
     
     
    PennyGovernance Vision
    Every success must begin with a vision. If you can see it, you can achieve it.
    crownequityholdings.com |  pennyotcstock.com |  crwenewswire.com |  crwefinance.com |  doubleinstocks.com |  crwedomains.com |  stock-ir.com |  drstockpick.com |  crwewallstreet.com |  stockhottips.com |  stock-pr.com |  pennyomega.com |  doctorstockpick.com |  bestotc.com |  crwepicks.com |  crweselect.com |  pennygovernance.com